PE20120307A1 - Derivados de indazol como antagonistas del receptor ccr4 - Google Patents
Derivados de indazol como antagonistas del receptor ccr4Info
- Publication number
- PE20120307A1 PE20120307A1 PE2011001557A PE2011001557A PE20120307A1 PE 20120307 A1 PE20120307 A1 PE 20120307A1 PE 2011001557 A PE2011001557 A PE 2011001557A PE 2011001557 A PE2011001557 A PE 2011001557A PE 20120307 A1 PE20120307 A1 PE 20120307A1
- Authority
- PE
- Peru
- Prior art keywords
- alkyl
- methyl
- halogen
- antagonists
- thenyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Otolaryngology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
REFERIDA A UN COMPUESTO DERIVADO DE INDAZOL DE FORMULA (I), DONDE R1 ES UN GRUPO -CH2-NH-(C=O)-A (FORMULA a), UN GRUPO -CH2-NH-SO2-B (FORMULA b), -C(O)NRaRb, CH2C(O)NRaRb, ENTRE OTROS; A ES H, ALQUILO C1-C6, CICLOALQUILO C3-C7, NRaRb, ENTRE OTROS; B ES ALQUILO C1-C6; Ra Y Rb SON H O ALQUILO C1-C6; R2 ES HALOGENO, ALQUILO C1-C6, CF3, HIDROXI O ALCOXI C1-C6; R3 ES HALOGENO, CF3, HIDROXILO, ALCOXI C1-C6, CH2OH O CHF2; R4 ES H, HALOGENO, ALQUILO C1-C6 O CF3; R5 Y R6 SON H, HALOGENO O ALQUILO C1-C6; n ES 0 O 1. SON COMPUESTOS PREFERIDOS: N-[(3-{[3-{[(5-CLORO-2-TIENIL)SULFONIL]AMINO}-4-(METILOXI)-1H-INDAZOL-1-IL] METIL}FENIL)METIL]ACETAMIDA, N-[(3-{[3-{[(5-CLORO-2-TIENIL)SULFONIL]AMINO}-4-(METILOXI)-1H-INDAZOL-1-IL]METIL}FENIL)METIL]-2-HIDROXI-2-METILPROPANAMIDA, N-[(3-{[3-{[(5-CLORO-2-TIENIL)SULFONIL]AMINO}-4-(METILOXI)-1H-INDAZOL-1-IL]METIL}FENIL)METIL]-3-MORFOLINCARBOXAMIDA, ENTRE OTROS. TAMBIEN ESTA REFERIDA A UNA COMPOSICION FARMACEUTICA Y A UN PROCEDIMIENTO DE PREPARACION. DICHOS COMPUESTOS SON ANTAGONISTAS DEL RECEPTOR CCR4 Y SON UTILES EN EL TRATAMIENTO DE EPOC, ASMA, RINITIS, FIBROSIS PULMONAR, ENTRE OTROS
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15570209P | 2009-02-26 | 2009-02-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20120307A1 true PE20120307A1 (es) | 2012-04-04 |
Family
ID=42110309
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2011001557A PE20120307A1 (es) | 2009-02-26 | 2010-02-24 | Derivados de indazol como antagonistas del receptor ccr4 |
Country Status (31)
Country | Link |
---|---|
US (3) | US8304446B2 (es) |
EP (1) | EP2401270B1 (es) |
JP (1) | JP5520969B2 (es) |
KR (1) | KR20110128896A (es) |
CN (1) | CN102388039B (es) |
AR (1) | AR075594A1 (es) |
AU (2) | AU2010217629A1 (es) |
BR (1) | BRPI1013396A2 (es) |
CA (1) | CA2753337A1 (es) |
CL (1) | CL2011002103A1 (es) |
CO (1) | CO6420342A2 (es) |
DK (1) | DK2401270T3 (es) |
DO (1) | DOP2011000272A (es) |
EA (1) | EA021740B1 (es) |
ES (1) | ES2439773T3 (es) |
HK (1) | HK1159621A1 (es) |
HR (1) | HRP20131174T1 (es) |
IL (1) | IL214655A0 (es) |
MA (1) | MA33132B1 (es) |
MX (1) | MX2011008972A (es) |
NZ (1) | NZ594641A (es) |
PE (1) | PE20120307A1 (es) |
PL (1) | PL2401270T3 (es) |
PT (1) | PT2401270E (es) |
RS (1) | RS53133B (es) |
SG (1) | SG173768A1 (es) |
SI (1) | SI2401270T1 (es) |
SM (1) | SMT201400001B (es) |
TW (1) | TW201041879A (es) |
UY (1) | UY32464A (es) |
WO (1) | WO2010097395A1 (es) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20100055456A (ko) | 2007-08-31 | 2010-05-26 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 다환식 화합물 |
EP2401277A1 (en) | 2009-02-26 | 2012-01-04 | Eisai R&D Management Co., Ltd. | Salt of tetrahydrotriazolopyridine derivative and crystal thereof |
CA2753696A1 (en) | 2009-02-26 | 2010-09-02 | Noritaka Kitazawa | Nitrogen-containing fused heterocyclic compounds and their use as beta amyloid production inhibitors |
US8729260B2 (en) * | 2010-05-19 | 2014-05-20 | Savior Lifetec Corporation | Process for the preparation of carbapenem using cabapenem intermediates and recovery of cabapenem |
WO2012025473A1 (en) * | 2010-08-24 | 2012-03-01 | Glaxo Group Limited | Cc.chemokine receptor 4 antagonists |
WO2015127125A1 (en) * | 2014-02-20 | 2015-08-27 | Cornell University | Compounds and methods for inhibiting fascin |
US10179787B2 (en) * | 2016-07-29 | 2019-01-15 | Flx Bio, Inc. | Chemokine receptor modulators and uses thereof |
WO2018049271A1 (en) | 2016-09-09 | 2018-03-15 | Flx Bio, Inc. | Chemokine receptor modulators and uses thereof |
JOP20190192A1 (ar) * | 2017-03-01 | 2019-08-08 | Glaxosmithkline Ip No 2 Ltd | مشتقات بيرازول بوصفها مثبطات برومودومين |
WO2018187509A1 (en) | 2017-04-04 | 2018-10-11 | Flx Bio, Inc. | Heterocyclic compounds as chemokine receptor modulators |
KR102615821B1 (ko) * | 2017-04-11 | 2023-12-21 | 선샤인 레이크 파르마 컴퍼니 리미티드 | 불소-치환된 인다졸 화합물 및 이의 용도 |
JP2021502345A (ja) | 2017-11-06 | 2021-01-28 | ラプト・セラピューティクス・インコーポレイテッド | 抗がん剤 |
CN110028501B (zh) | 2018-01-12 | 2022-02-22 | 迈德欣国际有限公司 | 化合物及其制备方法和用途 |
RU2020128176A (ru) | 2018-01-26 | 2022-03-02 | Рапт Терапьютикс, Инк. | Модуляторы рецепторов хемокинов и их применение |
CN113893220A (zh) * | 2020-07-07 | 2022-01-07 | 迈德欣国际有限公司 | 鼻粘膜给药剂型和其应用 |
US20230322741A1 (en) | 2022-04-06 | 2023-10-12 | Rapt Therapeutics, Inc. | Chemokine receptor modulators and uses thereof |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MXPA05005554A (es) * | 2002-12-12 | 2005-07-26 | Aventis Pharma Sa | Derivados de aminoindazol y su utilizacion como inhibidores de quinasas. |
FR2848554A1 (fr) * | 2002-12-12 | 2004-06-18 | Aventis Pharma Sa | Nouveaux derives d'aminoindazoles a titre de medicaments et compositions pharmaceutiques les renfermant |
SE0301650D0 (sv) * | 2003-06-04 | 2003-06-04 | Astrazeneca Ab | Novel compounds |
US20080194557A1 (en) * | 2007-01-18 | 2008-08-14 | Joseph Barbosa | Methods and compositions for the treatment of pain, inflammation and cancer |
-
2010
- 2010-02-24 MA MA34179A patent/MA33132B1/fr unknown
- 2010-02-24 MX MX2011008972A patent/MX2011008972A/es active IP Right Grant
- 2010-02-24 US US12/711,283 patent/US8304446B2/en not_active Expired - Fee Related
- 2010-02-24 BR BRPI1013396A patent/BRPI1013396A2/pt not_active IP Right Cessation
- 2010-02-24 AR ARP100100532A patent/AR075594A1/es not_active Application Discontinuation
- 2010-02-24 UY UY0001032464A patent/UY32464A/es not_active Application Discontinuation
- 2010-02-24 KR KR1020117022518A patent/KR20110128896A/ko not_active Application Discontinuation
- 2010-02-24 AU AU2010217629A patent/AU2010217629A1/en not_active Abandoned
- 2010-02-24 CN CN201080016319.3A patent/CN102388039B/zh not_active Expired - Fee Related
- 2010-02-24 ES ES10705594.9T patent/ES2439773T3/es active Active
- 2010-02-24 PT PT107055949T patent/PT2401270E/pt unknown
- 2010-02-24 NZ NZ594641A patent/NZ594641A/xx not_active IP Right Cessation
- 2010-02-24 TW TW099105340A patent/TW201041879A/zh unknown
- 2010-02-24 SG SG2011059813A patent/SG173768A1/en unknown
- 2010-02-24 PL PL10705594T patent/PL2401270T3/pl unknown
- 2010-02-24 RS RS20130585A patent/RS53133B/en unknown
- 2010-02-24 DK DK10705594.9T patent/DK2401270T3/da active
- 2010-02-24 JP JP2011551485A patent/JP5520969B2/ja not_active Expired - Fee Related
- 2010-02-24 WO PCT/EP2010/052307 patent/WO2010097395A1/en active Application Filing
- 2010-02-24 CA CA2753337A patent/CA2753337A1/en not_active Abandoned
- 2010-02-24 SI SI201030466T patent/SI2401270T1/sl unknown
- 2010-02-24 EP EP10705594.9A patent/EP2401270B1/en active Active
- 2010-02-24 PE PE2011001557A patent/PE20120307A1/es not_active Application Discontinuation
- 2010-02-24 US US13/202,139 patent/US8357716B2/en not_active Expired - Fee Related
- 2010-02-24 EA EA201190142A patent/EA021740B1/ru not_active IP Right Cessation
-
2011
- 2011-08-15 IL IL214655A patent/IL214655A0/en unknown
- 2011-08-25 DO DO2011000272A patent/DOP2011000272A/es unknown
- 2011-08-26 CL CL2011002103A patent/CL2011002103A1/es unknown
- 2011-08-26 CO CO11109505A patent/CO6420342A2/es active IP Right Grant
-
2012
- 2012-01-04 HK HK12100042.4A patent/HK1159621A1/xx not_active IP Right Cessation
- 2012-10-02 US US13/633,382 patent/US8507543B2/en not_active Expired - Fee Related
-
2013
- 2013-12-10 HR HRP20131174AT patent/HRP20131174T1/hr unknown
-
2014
- 2014-01-03 SM SM201400001T patent/SMT201400001B/xx unknown
-
2016
- 2016-06-02 AU AU2016203684A patent/AU2016203684A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20120307A1 (es) | Derivados de indazol como antagonistas del receptor ccr4 | |
CY1122610T1 (el) | Αλκοξυ πυραζολια ως ενεργοποιητες διαλυτης γουανυλικης κυκλασης | |
NO20091560L (no) | Biaryleterureaforbindelser | |
PE20091623A1 (es) | DERIVADOS DE 1H-PIRAZOLO[3,4-b]PIRIDINA COMO INHIBIDORES DE RAF QUINASA | |
ECSP14013173A (es) | 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil) carbamimidoil)pirazina-2-carboxamida | |
PE20070069A1 (es) | Piperazin-piperidinas como antagonistas y agonistas del receptor 5-ht1a | |
EA201891964A1 (ru) | СПОСОБ ПОЛУЧЕНИЯ МЕТИЛ{4,6-ДИАМИНО-2-[1-(2-ФТОРБЕНЗИЛ)-1H-ПИРАЗОЛО[3,4-b]ПИРИДИН-3-ИЛ]ПИРИМИДИН-5-ИЛ}МЕТИЛКАРБАМАТА И ЕГО ОЧИСТКИ ДЛЯ ПРИМЕНЕНИЯ В КАЧЕСТВЕ ФАРМАЦЕВТИЧЕСКОГО БИОЛОГИЧЕСКИ АКТИВНОГО ВЕЩЕСТВА | |
AR074676A1 (es) | Derivados de isooxazol como antagonistas de receptores de acido lisofosfatidico, composicion farmaceutica que los comprende y su uso en el tratamiento de enfermedades mediadas por la actividad fisiologica de lpa. | |
AU2018236805B2 (en) | Glutarimide derivatives, use thereof, pharmaceutical composition based thereon and methods for producing glutarimide derivatives | |
PE20110835A1 (es) | Piridiloxi-indoles inhibidores del vegf-r2 y uso de los mismos para el tratamiento de enfermedades | |
PE20120355A1 (es) | DERIVADOS DE PIRAZOL COMO INHIBIDORES DE LA ENZIMA 11ßHSD1 | |
EA200900658A1 (ru) | Производные индазолилэфиров или -амидов для лечения расстройств, опосредованных глюкокортиодными рецепторами | |
MA32175B1 (fr) | Oxadiazoanthracènes pour le traitement du diabète | |
ATE538100T1 (de) | Aminotetrahydroindazoloessigsäuren | |
NZ595759A (en) | Substituted phenylureas and phenylamides as vanilloid receptor ligands | |
MX2013008213A (es) | N-[3-(5-amino-3,3a,7,7a-tetrahidro-1h-2,4-dioxa-6-aza-inden-7-il) -fenil]-amidas como inhibidores de beta-secretasa 1 (bace1) y/o beta-secretasa 2 (bace2). | |
MX2014003408A (es) | N-(3-(2-amino-6,6-difluor-4,4a,5,6,7,7a-hexahidro-ciclopenta-[e][ 1,3]oxazin-4-il)-fenil)-amidas como inhibidores de la beta-secretasa 1 (bace1). | |
PE20090333A1 (es) | Oxazolidinonas sustituidas y su uso | |
MX350862B (es) | Acidos de piperidinil naftilacetico. | |
PE20090620A1 (es) | Derivados de 1,2,4,5-tetrahidro-3h-benzazepinas, su procedimiento de preparacion y las composiciones farmaceuticas que las contienen | |
PE20110703A1 (es) | Acidos naftilaceticos | |
PE20110710A1 (es) | Acidos naftilaceticos | |
PE20110928A1 (es) | Derivados de 4-azetidinil-1-heteroaril-ciclohexanol como antagonistas de ccr2 | |
PE20061363A1 (es) | Derivados de 4-fenil-5-oxo-1,4,5,6,7,8-hexahidroquinolina como agonistas del receptor fsh | |
EA200701879A1 (ru) | Замещённые производные оксадиазаспиро [5.5] ундеканона и их применение в качестве антагонистов нейрокинина |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant, registration | ||
FD | Application declared void or lapsed |